Intended for US Healthcare Professionals Only

Important Safety Information » | Full Prescribing Information »

THE FIRST AND ONLY HRIG STUDIED IN PEDIATRIC PATIENTS1

Learn more about the safety and efficacy results of KEDRAB® (Rabies Immune Globulin [Human]), which was shown to be appropriate and effective for use as an important component of post-exposure prophylaxis (PEP) in a Phase 4 clinical study of pediatric patients.1

KEDRAB is designed, dosed, and packaged in accordance with American Society of Hospital Pharmacists (ASHP) guidelines on preventing medication errors.2

References: 1. Hobart-Porter N, Stein M, Toh N, Amega N, Nguyen HB, Linakis J. Safety and efficacy of rabies immunoglobulin in pediatric patients with suspected exposure. Hum Vaccin Immunother. 2021;17(7):2090-2096. doi:10.1080/21645515.2020.1854000. 2. Billstein-Leber M, Carrillo CJD, Cassano AT, Moline K, Robertson JJ. ASHP Guidelines on Preventing Medication Errors in Hospitals. Am J Health Syst Pharm. 2018;75:1493-1517. doi:10.2146/ajhp170811.

SAME KEDRAB, IMPROVED PRODUCT PACKAGING

  • Enhanced color packaging for clear identification of 2mL and 10mL dosage options
  • User-friendly vertical barcodes on vials for easier scanning

New KEDRAB packaging, with distinctive vial sizes and colors, designed to reduce chances of error

Over the next several months, you can expect to start receiving KEDRAB® (Rabies Immune Globulin [Human]) with enhanced product packaging, as pictured above. Products with new packaging will be shipped when available, and after distributors' current supplies become depleted. As such, it is likely you may not receive both the new 2mL and 10mL product packaging at the same time.